Matches in SemOpenAlex for { <https://semopenalex.org/work/W1915041231> ?p ?o ?g. }
- W1915041231 abstract "Background Faecal incontinence (FI) and constipation are both socially‐embarrassing and physically‐disabling conditions that impair quality of life. For both, surgery may be required in a minority of people when more conservative measures fail. However, the invasiveness and irreversible nature of direct surgery on bowel and sphincter muscles, poor long‐term outcomes and well‐established compIications makes such procedures unappealing for these benign conditions. A less‐invasive surgical option to treat faecal incontinence and constipation is direct, low‐voltage stimulation of the sacral nerve roots, termed sacral nerve stimulation (SNS). SNS has become the first line surgical treatment for FI in people failing conservative therapies. Its value in the treatment of constipation is less clear. Objectives To assess the effects of sacral nerve stimulation using implanted electrodes for the treatment of faecal incontinence and constipation in adults. Search methods We searched the Cochrane Incontinence Group Specialised Register, which contains trials identified from the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, MEDLINE In‐Process, ClinicalTrials.gov, the World Health Organization (WHO) ICTRP and handsearched journals and conference proceedings (searched 5 February 2015), EMBASE (1 January 1947 to 2015 Week 5), and the reference lists of retrieved relevant articles. Selection criteria All randomised or quasi‐randomised trials assessing the effects of SNS for faecal incontinence or constipation in adults. Data collection and analysis Two review authors independently screened the search results, assessed the methodological quality of the included trials, and undertook data extraction. Main results Six crossover trials and two parallel group trials were included. Six trials assessed the effects of SNS for FI. In the parallel group trial conducted by Tjandra, 53 participants with severe FI in the SNS group experienced fewer episodes of faecal incontinence compared to the control group who received optimal medical therapy (mean difference (MD) −5.20, 95% confidence interval (CI) −9.15 to −1.25 at 3 months; MD −6.30, 95% CI −10.34 to −2.26 at 12 months). Adverse events were reported in a proportion of participants: pain at implant site (6%), seroma (2%) and excessive tingling in the vaginal region (9%). In the parallel group trial carried out by Thin, 15 participants with FI in the SNS group experienced fewer episodes of FI compared with the percutaneous tibial nerve stimulation (PTNS) group (MD −3.00, 95% CI −6.61 to 0.61 at 3 months; MD −3.20, 95% CI −7.14 to 0.74 at 12 months). Adverse events were reported in three participants: mild ipsilateral leg pain during temporary testing (n = 1); and stimulator‐site pain following insertion of neurostimulator (n = 2). In the crossover trial by Leroi 7 of 34 recruited participants were excluded from the crossover due mainly to complications or immediate device failure. Twenty‐four of the remaining 27 participants while still blinded chose the period of stimulation they had preferred. Outcomes were reported separately for 19 participants who preferred the 'on' and five who preferred the 'off' period. For the group of 19, the median (range) episodes of faecal incontinence per week fell from 1.7 (0 to 9) during the 'off' period to 0.7 (0 to 5) during the 'on' period; for the group of five, however, the median (range) rose from 1.7 (0 to 11) during the 'off' period compared with 3.7 (0 to 11) during the 'on' period. Four of 27 participants experienced an adverse event resulting in removal of the stimulator. In the crossover trial by Sørensen and colleagues, participants did not experience any FI episodes in either the one‐week ‘on’ or ‘off’ periods. In the crossover trial by Vaizey, participants reported an average of six, and one, episodes of faecal incontinence per week during the 'off' and 'on' periods respectively in two participants with FI. Neither study reported adverse events. In the crossover trial by Kahlke, 14 participants with FI experienced significantly lower episodes of FI per week during the stimulator 'on' (1 (SD, 1.7)) compared with the 'off' period (8.4 (SD, 8.7)). Adverse events reported include: haematoma formation (n = 3); misplacement of tined lead (1); and pain at stimulator site (n = 1). Two trials assessed SNS for constipation. In the Kenefick trial, the two participants experienced an average of two bowel movements per week during the 'off' crossover period, compared with five during the 'on' period. Abdominal pain and bloating occurred 79% of the time during the 'off' period compared with 33% during the 'on' period. No adverse events occurred. In contrast, in the trial by Dinning with 59 participants, SNS did not improve frequency of bowel movements and 73 adverse events were reported, which included pain at site of the implanted pulse generator (32), wound infection (12), and urological (17) events. Authors' conclusions The limited evidence from the included trials suggests that SNS can improve continence in a proportion of patients with faecal incontinence. However, SNS did not improve symptoms in patients with constipation. In addition, adverse events occurred in some patients where these were reported. Rigorous high quality randomised trials are needed to allow the effects of SNS for these conditions to be assessed with more certainty." @default.
- W1915041231 created "2016-06-24" @default.
- W1915041231 creator A5035866826 @default.
- W1915041231 creator A5039582875 @default.
- W1915041231 creator A5042206717 @default.
- W1915041231 creator A5046012946 @default.
- W1915041231 creator A5069444079 @default.
- W1915041231 date "2015-08-24" @default.
- W1915041231 modified "2023-09-26" @default.
- W1915041231 title "Sacral nerve stimulation for faecal incontinence and constipation in adults" @default.
- W1915041231 cites W1273379855 @default.
- W1915041231 cites W1507918272 @default.
- W1915041231 cites W1523167312 @default.
- W1915041231 cites W1555107348 @default.
- W1915041231 cites W1775035413 @default.
- W1915041231 cites W179591318 @default.
- W1915041231 cites W1819833485 @default.
- W1915041231 cites W1895501895 @default.
- W1915041231 cites W1922662203 @default.
- W1915041231 cites W1927554783 @default.
- W1915041231 cites W1934604585 @default.
- W1915041231 cites W1964479242 @default.
- W1915041231 cites W1970713273 @default.
- W1915041231 cites W1973982536 @default.
- W1915041231 cites W1974232038 @default.
- W1915041231 cites W1975869682 @default.
- W1915041231 cites W1976922308 @default.
- W1915041231 cites W1981331700 @default.
- W1915041231 cites W1982561746 @default.
- W1915041231 cites W1982907850 @default.
- W1915041231 cites W1983889266 @default.
- W1915041231 cites W1984382670 @default.
- W1915041231 cites W1988599517 @default.
- W1915041231 cites W1990159264 @default.
- W1915041231 cites W1992103194 @default.
- W1915041231 cites W1992552421 @default.
- W1915041231 cites W1994357295 @default.
- W1915041231 cites W1996626983 @default.
- W1915041231 cites W2000689591 @default.
- W1915041231 cites W2003424479 @default.
- W1915041231 cites W2006721040 @default.
- W1915041231 cites W2007826917 @default.
- W1915041231 cites W2010123869 @default.
- W1915041231 cites W2011144550 @default.
- W1915041231 cites W2013471072 @default.
- W1915041231 cites W2017984043 @default.
- W1915041231 cites W2018961807 @default.
- W1915041231 cites W2021379632 @default.
- W1915041231 cites W2024033249 @default.
- W1915041231 cites W2024151943 @default.
- W1915041231 cites W2031537125 @default.
- W1915041231 cites W2032552897 @default.
- W1915041231 cites W2034263371 @default.
- W1915041231 cites W2034447768 @default.
- W1915041231 cites W2034783885 @default.
- W1915041231 cites W2041581988 @default.
- W1915041231 cites W2042257850 @default.
- W1915041231 cites W2045276152 @default.
- W1915041231 cites W2055475241 @default.
- W1915041231 cites W2059918125 @default.
- W1915041231 cites W2060682031 @default.
- W1915041231 cites W2068454300 @default.
- W1915041231 cites W2073248260 @default.
- W1915041231 cites W2073611184 @default.
- W1915041231 cites W2076385877 @default.
- W1915041231 cites W2077597113 @default.
- W1915041231 cites W2077800346 @default.
- W1915041231 cites W2080299672 @default.
- W1915041231 cites W2080499387 @default.
- W1915041231 cites W2085307345 @default.
- W1915041231 cites W2088584672 @default.
- W1915041231 cites W2091997418 @default.
- W1915041231 cites W2096127740 @default.
- W1915041231 cites W2108007239 @default.
- W1915041231 cites W2115002011 @default.
- W1915041231 cites W2119674820 @default.
- W1915041231 cites W2131806107 @default.
- W1915041231 cites W2137077808 @default.
- W1915041231 cites W2138411755 @default.
- W1915041231 cites W2139006310 @default.
- W1915041231 cites W2140627274 @default.
- W1915041231 cites W2142138515 @default.
- W1915041231 cites W2142707382 @default.
- W1915041231 cites W2143666125 @default.
- W1915041231 cites W2143811824 @default.
- W1915041231 cites W2148439671 @default.
- W1915041231 cites W2162815630 @default.
- W1915041231 cites W2163203023 @default.
- W1915041231 cites W2172290329 @default.
- W1915041231 cites W2317072013 @default.
- W1915041231 cites W2326571525 @default.
- W1915041231 cites W2329509249 @default.
- W1915041231 cites W2335509757 @default.
- W1915041231 cites W2416368218 @default.
- W1915041231 cites W2417192683 @default.
- W1915041231 cites W2472719954 @default.
- W1915041231 cites W2964735029 @default.
- W1915041231 cites W4238651357 @default.
- W1915041231 cites W4240470140 @default.
- W1915041231 cites W4242303433 @default.